BIOT 232 |
| Protein engineering and design technologies offer the potential to engineer therapeutics that possess increased target specificity and binding affinity, and consequently, improved efficacy. Such approaches have renewed interest in peptides as therapeutics, and an increasing number of peptides are entering clinical trials. Meanwhile, peptides often exhibit poor efficacy in clinical trials, owing in part to their insufficient affinity, specificity, and stability. We have developed a set of new peptide engineering tools that significantly expand our capabilities for optimizing peptide properties for potential therapeutic application. These tools present the opportunity to generate and optimize peptides, for cell targeting, protease mediated activation, and specific inhibition, to more fully exploit distinct biological mechanisms to enhance efficacy. |
|
Emerging Technologies: Design and Engineering of Novel Therapeutic Strategies
3:00 PM-5:30 PM, Wednesday, 13 September 2006 Hilton San Francisco -- Yosemite B, Oral
Division of Biochemical Technology |